Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.41 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.41 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.40 |
| ▸ | TOP1 known ✓ | P11387 | 3/20 | 0.38 |
| ▸ | TOP2A known ✓ | P11388 | 3/20 | 0.38 |
| ▸ | TOP2B known ✓ | Q02880 | 3/20 | 0.38 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.34 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | SNCA | P37840 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FUT7 | Q11130 | 2/20 | 0.41 |
| ▸ | SELL | P14151 | 2/20 | 0.41 |
| ▸ | SELP | P16109 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168980 | 0.98 | KDM4E (0.42) | KDM4ELMNATDP1SNCAALDH1A1 | |
| SCHEMBL13924923 | 0.80 | PTGS2 (0.55) | KDM4ELMNATDP1FUT7CA12 | |
| SCHEMBL12348318 | 0.79 | HDAC8 (0.30) | HDAC6 | |
| SCHEMBL3237538 | 0.76 | TTR (0.48) | LMNATDP1ALDH1A1MAPTCA1 | |
| SCHEMBL8121970 | 0.74 | TTR (0.46) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL6377504 | 0.74 | HDAC6 (0.57) | KDM4ESNCAMAPTCA12CA1 | |
| SCHEMBL261652 | 0.74 | CA1 (0.44) | ALDH1A1CA1CA2GAAL3MBTL1 | |
| SCHEMBL261538 | 0.70 | GABRA1 (0.40) | ALDH1A1 | |
| SCHEMBL20580082 | 0.70 | SNCA (0.46) | KDM4ELMNASNCAHSD17B10HDAC6 | |
| SCHEMBL16706131 | 0.68 | PRSS1 (0.37) | HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2017-04-13 | — | — | US | disclosed |
| US-9526707-B2 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L (US) | 2016-12-27 | — | — | US | disclosed |
| EP-2030615-A2 | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases | ELFORD, Howard L. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | ELFORD HOWARD L | 2009-02-19 | — | — | US | disclosed |
| US-20060154892-A1 | Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis | LORI FRANCO | 2006-07-13 | — | — | US | disclosed |
| US-20060052317-A1 | Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis | LORI FRANCO | 2006-03-09 | — | — | US | disclosed |
| US-20030095988-A1 | Method of inducing autovaccination against HIV infection using structured treatment interruptions | LISZIEWICZ JULIANNA (US) | 2003-05-22 | — | — | US | disclosed |
| WO-2002095005-A2 | THERAPEUTIC DNA VACCINATION | LISZIEWICZ JULIANNA (US) | 2002-11-28 | — | — | WO | disclosed |
| US-20020022034-A1 | Antiretroviral therapy | LISZIEWICZ JULIANNA (US) | 2002-02-21 | — | — | US | disclosed |
| US-20010008905-A1 | Procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis | LORI FRANCO (IT) | 2001-07-19 | — | — | US | disclosed |
| US-6251874-B1 | IF HIV VIRAL LOAD IN BLOOD OF PATIENT IS ABOVE SPECIFIED AMOUNT, ADMINISTERING HYDROXYUREA, DIDEOXYINOSINE AND INDINAVIR UNTIL VIRAL LOAD IS REDUCED; IF VIRAL LOAD IS BELOW THAT SPECIFIED, ADMINISTERING HYDROXYUREA AND DIDEOXYINOSINE | RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY (R.I.G.H.T.) | 2001-06-26 | — | — | US | disclosed |
| US-6194390-B1 | ADMINISTERING HYDROXYUREA AND A 2'-FLUOROPURINE-DIDEOXY-NUCLEOSIDE SELECTED FROM THE GROUP OF 2'-FLUORO-2',3'-DIDE-OXYADENOSINE,-DIDEOXYINOSINE, AND -DIDEOXYGUANOSINE WITH A CARRIER OR EXCIPIENT; VIRICIDES; RETROVIRUSES; PLANT VIRUSES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-02-27 | — | — | US | disclosed |
| US-6114312-A | SYNERGISTIC MIXTURE; PREVENTIO REPLICATION OF REVERSE TRANSCRIPTASE VIRUS | RESEARCH INSTITUTE FOR GENETIC AND HUMAN THERAPY (R.I.G.H.T.) (US) | 2000-09-05 | — | — | US | disclosed |
| US-5977086-A | Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor | R.I.G.H.T. (US) | 1999-11-02 | — | — | US | disclosed |
| US-5350770-A | Administering hydroxy benzamide derivative | ELFORD HOWARD L (US) | 1994-09-27 | — | — | US | disclosed |
| WO-1994002135-A1 | THERAPEUTIC PROCESS FOR THE TREATMENT OF SEPTIC SHOCK | ELFORD HOWARD L (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047250-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | CA2 3757/4885DPP4 1052/4885GAA 1275/4885 |
| US-20170100352-A1 | Methods for treating or preventing neuroinflammation or autoimmune diseases | RNASE1, RNASEH1, TXNRD3 | CA2 3757/4885DPP4 1052/4885GAA 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.